Recent published and unpublished studies from our laboratory suggest aberrant expression of a novel transmembrane mucin, MUC13, in ovarian and pancreatic cancers. We have also shown that exogenous MUC13 expression enhances cellular motility, invasion, proliferation and tumorigenesis of ovarian and pancreatic cancer cell lines. These effects are associated with modulation of HER2 and p53 expression. As supported by our preliminary data, we propose that the overexpression of MUC13 contributes to the pathogenesis of pancreatic cancer. In this grant proposal, our objectives are to delineate the functional aspects of MUC13 mucin in pancreatic cancer. We hypothesize that the different domains of MUC13 execute specific functions in cancer cells and their suppression will diminish pancreatic cancer cell growth and tumorigenesis. Additionally, we hypothesize that the aberrant MUC13 expression operates as an oncoprotein via interaction/stabilization/activation of EGFRs (HER1, HER2) and suppression of p53. To test these hypotheses, we propose three specific aims. 1) To investigate the roles of different MUC13 domains in the function and the signaling pathways modulated by MUC13 in pancreatic cancer cells. 2) To investigate whether the effect of MUC13 on tumorigenesis is mediated through EGFRs (HER1, HER2) and/or the tumor suppressor p53. In this aim we propose to determine if MUC13 physically interacts with EGFRs and/or p53 and influences expression of these proteins. 3) Develop novel methods for targeted repression of MUC13 expression in pancreatic tumors and targeted inhibition of pancreatic cancer cell growth. In this aim we will generate PLGA nanoparticle formulations of MUC13 siRNA and ormeloxifene (an anti- cancer drug), coupled with anti-MUC13 MAbs for their sustained and targeted delivery specifically in pancreatic tumors. Taken together, this information will provide important insights for developing novel therapeutic strategies for pancreatic cancer.
With a very low survival rate, pancreatic cancer is one the most lethal malignancies, primarily due to the lack of early diagnostic markers and limited information regarding the molecular mechanisms surrounding pancreatic cancer. Understanding of the molecular mechanisms of pancreatic cancer progression and the identification of early diagnostic markers may significantly reduce the deaths caused by pancreatic cancer.
|Gara, Rishi K; Kumari, Sonam; Ganju, Aditya et al. (2015) Slit/Robo pathway: a promising therapeutic target for cancer. Drug Discov Today 20:156-64|
|Khan, Sheema; Ebeling, Mara C; Zaman, Mohd S et al. (2014) MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget 5:7599-609|
|Sundram, Vasudha; Ganju, Aditya; Hughes, Joshua E et al. (2014) Protein kinase D1 attenuates tumorigenesis in colon cancer by modulating ?-catenin/T cell factor activity. Oncotarget 5:6867-84|
|Ganju, Aditya; Yallapu, Murali M; Khan, Sheema et al. (2014) Nanoways to overcome docetaxel resistance in prostate cancer. Drug Resist Updat 17:13-23|
|Yallapu, Murali M; Khan, Sheema; Maher, Diane M et al. (2014) Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 35:8635-48|
|Gara, Rishi Kumar; Sundram, Vasudha; Chauhan, Subhash C et al. (2013) Anti-cancer potential of a novel SERM ormeloxifene. Curr Med Chem 20:4177-84|
|Yallapu, Murali M; Jaggi, Meena; Chauhan, Subhash C (2013) Curcumin nanomedicine: a road to cancer therapeutics. Curr Pharm Des 19:1994-2010|
|Yallapu, Murali M; Ebeling, Mara C; Jaggi, Meena et al. (2013) Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Curr Drug Metab 14:504-15|
|Yallapu, Murali M; Ebeling, Mara C; Khan, Sheema et al. (2013) Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther 12:1471-80|
|Khan, Sheema; Ansarullah; Kumar, Deepak et al. (2013) Targeting microRNAs in pancreatic cancer: microplayers in the big game. Cancer Res 73:6541-7|
Showing the most recent 10 out of 17 publications